• Breast cancer: major flaws in study calling for expanded genetic testing
    Breast cancer: major flaws in study calling for expanded genetic testing

    Cambridge researchers slam a Journal of Clinical Oncology paper recommending genetic testing for all patients.

  • Promising new treatment for advanced refractory solid tumours
    Promising new treatment for advanced refractory solid tumours

    Further studies of the treatment for HER2-low breast cancer and other HER2-expressing cancers are planned.

  • BCa: residual nodal disease after neoadjuvant chemo linked to poorer prognosis

    Around 2x worse DFS and OS relative to node-negative patients.

  • Is annual better than biennial mammography for high-risk women aged 50-74 years?

    A Canadian cohort study finds higher sensitivity but lower specificity for certain groups of high-risk women.

  • Breast cancer: ER+ and PR+ fare worse than ER+PR+ patients

    Results of a meta-analysis.

  • 3D mammography adoption triples in 3 years

    DBT has a lower recall rate and a higher cancer detection rate.

  • HR+ BCa: high-dose vitamin D fails to prevent aromatase inhibitor-induced arthralgia

    Study terminated early, based on results of planned futility analysis.

  • Breast cancer: palbociclib-related neutropenia mostly transient, manageable

    Dose modifications did not compromise efficacy in PALOMA-2.

  • New genetic variant linked to pre-menopausal breast cancer
    New genetic variant linked to pre-menopausal breast cancer

    Replication of previous findings in Caucasian women and validation in African and Asian populations.

  • Alcohol underrecognized as a risk factor for breast cancer

    Low alcohol literacy is common among mammography attenders and staff.

  • Add-on zoledronic acid shows benefit in neoadjuvant breast cancer

    Phase 2 data show 42% pathologic complete response rate.

  • Breast cancer: MRI-based screening tops mammography in women with familial risk

    Earlier disease detection, but false-positives may still be an issue.

  • Young age at diagnosis tied to poorer breast cancer outcomes

    Very young patients merit their own subgroup for clinical trials and further research.

  • Metastatic TNBC: phase 2 points to benefit with niraparib + pembrolizumab

    Numerically higher response rates in patients with tumor BRCA mutations.

  • Load more